What are the treatment options for patients with MCL who relapse after BTKi therapy?

During the European Hematology Association (EHA) 2023 Congress, the Lymphoma Hub spoke to Chan Cheah, Sir Charles Gairdner Hospital, Perth, AU. We asked, What are the treatment options for patients with MCL who relapse after BTKi therapy?

Outcomes for patients with mantle cell lymphoma (MCL) treated with covalent Bruton's tyrosine kinase inhibitors (BTKi) can be poor, with a median overall survival of 6–12 months. Here, Cheah discusses the benefits and drawbacks of different agents considered for patients with BTKi relapsed/refractory MCL, including chimeric antigen receptor T-cell therapies, non-covalent BTKis, and bi-specific antibodies. Not all these therapies are globally available; therefore, he discusses the importance of enrolling patients with MCL for clinical trials to help develop new treatments.